Application of HIF2alpha agonist and ACER2 agonist in preparation of medicine for treating atherosclerosis

Abstract

The invention discloses application of an HIF2alpha agonist and an ACER2 agonist in preparation of a medicine for treating and / or preventing atherosclerosis. Wherein the HIF2alpha agonist can be an adipose cell HIF2alpha agonist, and the ACER2 agonist can be a visceral fat ACER2 enzyme activator. The invention also discloses an application of Roxadustat in preparing a medicine for treating and / orpreventing atherosclerosis. The HIF2alpha agonist, the ACER2 agonist and the Roxadustat can be used for inhibiting or alleviating the occurrence and development of atherosclerosis.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to the use of HIF2α agonists and ACER2 agonists in preparing medicines for treating atherosclerosis. Background technique [0002] Atherosclerotic disease (AS) is a chronic metabolic cardiovascular disease and an important cause of death worldwide. Chronic inflammation and dyslipidemia are the main pathological features of the occurrence and development of AS. AS lesions start from the activation of endothelial cells, and the progressive deposition of lipids in the vessel wall induces the adhesion and infiltration of monocytes, proliferates and differentiates into macrophages under the action of cytokines. The formation of foam cells and the proliferation of smooth muscle cells are the main features of AS. Macrophages express a large number of scavenger receptors, and the modified low-density lipoprotein (low density lipoprotein, LDL) is absorbed by the scavenger receptors to ...

AI Technical Summary

Problems solved by technology

[0004] However, while the benefits of high-intensity statins are increasing, their potential harms will also increase. In severe cases, they may even lead to cancer, elevated liver enzymes, myositis and myopathy, diabetes and cognitive dysfunction (such as Al Alzheimer's disease and dementia), and patients are highly dependent on drugs, once the drug is stopped, some symptoms will still persist

PCSK9 inhibitors and PCSK9 antibody vaccines are not only extremely expensive, but their clinical safety and whether there are other side effects still need further verification

Images